文献速递头颈外科

口咽癌数据集间的临床异质性及其对结局预测的影响

Clinical Heterogeneity Across Oropharyngeal Cancer Datasets and Implications for Outcome Prediction.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-10-22

该研究对比RADCURE与HNSCC-Oropharyngeal两个口咽癌数据集,发现机构间在人口学、HPV分布和治疗方式上存在显著异质性;调整后治疗机构的风险比为1.19(95%CI 0.93-1.52),未独立预测生存,机器学习模型区分度中等至良好。

要点

  • 多机构口咽癌数据集合并分析前需系统协调变量与编码
  • HPV状态违反比例风险假设,宜用限制平均生存时间量化效应
  • 调整后治疗机构未独立预测生存,但异质性仍可引入偏倚

核心结论

  • 多机构口咽癌数据集存在显著异质性,合并分析前需系统协调与假设检验。
  • 充分调整后,治疗机构未独立预测生存,风险比1.19(95%CI 0.93-1.52)。

研究设计与样本

  • 横断面分析与回顾性队列研究,纳入RADCURE(2005-2017)和HNSCC-Oropharyngeal(2005-2012)数据集。
  • 最终分析队列1972例,中位年龄59.5岁(IQR 53.4-67.0),女性347例(17.6%),男性1625例(82.4%)。
  • RADCURE贡献1482例,HNSCC-Oropharyngeal贡献490例;HPV阳性1263例(64.0%)。
  • 采用Kaplan-Meier分析、Peto-Peto加权log-rank检验、限制平均生存时间和多变量Cox回归(按HPV分层)。
  • 机器学习评估1年、5年、10年生存预测的区分度与校准度。

主要发现

  • 两机构在人口学特征、HPV分布和治疗方式上存在显著差异。
  • 调整后治疗机构风险比1.19(95%CI 0.93-1.52),未排除临床有意义效应。
  • HPV状态违反比例风险假设,限制平均生存时间显示两个数据集中HPV阳性患者均有临床有意义的生存优势。
  • 机器学习集成模型区分度中等至良好:1年AUC 0.820,5年AUC 0.777,10年AUC 0.786。
  • 机构在预测模型中始终为低重要性预测因子。

关键数值与推荐

  • 多机构口咽癌分析前应进行系统协调并严格检验模型假设。
  • HPV状态违反比例风险假设时,应采用限制平均生存时间等方法量化其预后效应。

临床怎么用

  • 合并多机构口咽癌数据前,应系统评估变量可用性、编码约定和患者特征异质性。
  • 对HPV状态等违反比例风险假设的变量,避免仅依赖Cox模型风险比,可补充限制平均生存时间。
  • 治疗机构可作为异质性来源纳入考量,但调整后其本身不独立预测生存。

局限性

  • 仅纳入两个机构数据集,结论外推需谨慎。
  • 仅纳入患者和疾病特征数据完整的患者,可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Multi-institutional oropharyngeal cancer datasets are increasingly used for research, yet systematic evaluation of data completeness and its clinical impact remains limited. Unrecognized institutional heterogeneity in variable availability, coding conventions, and patient characteristics can introduce substantial bias into combined analyses. OBJECTIVE: To systematically characterize data availability patterns and clinical heterogeneity across 2 major oropharyngeal cancer datasets, evaluate their impact on survival, and develop evidence-based recommendations for multi-institutional research design. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional analysis and retrospective cohort study was conducted of the RADCURE dataset (2005-2017) from Princess Margaret Cancer Centre (Toronto, Canada) and the HNSCC-Oropharyngeal dataset (2005-2012) from MD Anderson Cancer Center (Houston, Texas). Patients with complete data on patient and disease characteristics were included. Data were analyzed from 2023 to 2026. EXPOSURES: Institutional dataset, human papillomavirus (HPV) status, tumor (T) stage, node (N) stage, harmonized treatment modality, smoking status, and age at diagnosis. MAIN OUTCOMES AND MEASURES: Data completeness rates across clinical and end point variables; overall survival assessed using Kaplan-Meier analysis with Peto-Peto weighted log-rank tests, restricted mean survival time, and multivariable Cox proportional hazards regression stratified by HPV status; machine learning discrimination and calibration for 1-, 5-, and 10-year survival prediction. RESULTS: The final analytic cohort comprised 1972 participants (median [IQR] age, 59.5 [53.4-67.0] years; 347 female [17.6%] and 1625 male [82.4%] individuals), 1482 from the RADCURE and 490 from the HNSCC-Oropharyngeal datasets. Of the total, 1263 had HPV-positive disease (64.0%). Substantial institutional differences were observed across demographic characteristics, HPV distribution, and treatment modality. After comprehensive adjustment, the hazard ratio for treating institutions was 1.19 (95% CI, 0.93-1.52), not excluding a clinically meaningful effect. HPV status violated the proportional hazards assumption, and its prognostic effect was quantified using restricted mean survival time, demonstrating a clinically meaningful survival advantage for patients with HPV-positive disease in both datasets. Machine learning ensemble models achieved moderate to good discrimination (1-year area under the curve [AUC], 0.820; 5-year AUC, 0.777; 10-year AUC 0.786) with institution consistently ranking as a low-importance predictor. CONCLUSIONS AND RELEVANCE: In this cross-sectional analysis and cohort study, multi-institutional oropharyngeal cancer datasets exhibited substantial heterogeneity requiring systematic harmonization prior to combined analyses. Systematic harmonization and rigorous assumption testing should be prerequisites for multi-institutional oropharyngeal cancer analyses; after appropriate adjustment, treating institution did not independently predict survival.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Cabrera CI, Tamaki A, Koroukian SM, et al. Clinical Heterogeneity Across Oropharyngeal Cancer Datasets and Implications for Outcome Prediction. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42911606. doi:10.1001/jamaoto.2026.3290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。